Search our team at AdventHealth Research Institute
-
NCT06282575
An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer
This study is currently enrolling.Associated Conditions: Liver CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThis is an open-label, randomized, multicenter, phase 3 study to investigate the efficacy and safety of zanidatamab plus CisGem with or without a PD-1/L1 inhibitor (physician’s choice of either...
-
NCT06191744
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
This study is currently enrolling.Associated Conditions: LymphomaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe primary objective of the study is to demonstrate that epcoritamab
with R2 (ER2) will improve CR30 rates compared to chemoimmunotherapy
(CIT) in subjects with previously untreated FL. The primary... -
NCT04408625
A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)
This study is currently enrolling.Associated Conditions: AlzheimersResearch Area: Neuroscience ResearchResearch Location: Orlando, FloridaThe purpose of this open label study is to assess the safety, tolerability, and effects of LY3884963 on plasma (the liquid component of blood) and/or cerebrospinal fluid (CSF; fluid from the area...
-
NCT04127578
Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients with Parkinson’s Disease with at Least One GBA1 Mutation (PROPEL)
This study is currently enrolling.Research Area: Neuroscience ResearchResearch Location: Orlando, FloridaParkinson’s disease is a slowly progressive and disabling disease of the central nervous system that causes problems with movement, such as shaking, stiffness, slow movement, and difficulty walking...
-
NCT05901831
FINE-ONE: A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of Finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease and type 1 diabetes
This study is currently enrolling.Research Area: Translational ResearchResearch Location: Orlando, FloridaStudy Purpose: The aim of the study is to demonstrate efficacy of Finerenone when compared to placebo, in addition to standard of care, in delaying the progression of chronic kidney disease (CKD) in...
-
Long-Term Follow-up Study (LTFS): An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, FloridaCaribou's CAR-T cell product is a genetically modified cell therapy, meaning it is designed to change the expression of a gene or alter natural properties of living cells. Healthy donor T cells have...
-
NCT06072612
A Phase 3 Randomized, Open-label Study Comparing the Bria-IMT regimen in combination with Check Point Inhibitor vs Physician’s Choice in Metastatic Breast Cancer (BRIA-ABC)
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this research study is to assess the safety and effectiveness of an experimental therapy for advanced breast cancer called Bria-IMT (SV-BR-1-GM) in combination with the immune...
-
NCT06132893
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of the BHV7000 in Subjects with Refractory Focal Onset Epilepsy
This study is currently enrolling.Research Area: Neuroscience ResearchResearch Location: Orlando, FloridaThis is a research study to test a new investigational drug. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA). The main purpose of this study...
-
NCT06008093
D419ML00003: A Phase IIIb, Randomized, Multicenter, Open-label study, to assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination with Platinum Based Chemotherapy for First Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients who have Mutations or Co mutations in STK11, KEAP1, or KRAS (TRITON)
This study is currently enrolling.Associated Conditions: Lung CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaTo assess the efficacy of durvalumab plus tremelimumab plus chemotherapy compared with pembrolizumab plus chemotherapy in terms of OS, in participants with non-squamous histology who have metastatic...
-
NCT5812807
Optimice-PCR: De-Escalation Of Therapy In Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThis study is being done to answer the following question: Among patients with early-stage TNBC who achieve a pCR after preoperative chemotherapy in combination with pembrolizumab, will observation...
-
NCT06072781
VS-6766-301/GOG-3097 A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
This study is currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe main aims of this clinical study are to: Find out if the combination of avutometinib (VS-6766) and defactinib is better at prolonging the time it takes for LGSOC to grow compared to standard of...
-
NCT05154487
GOG 3069 Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-positive Endometrioid Endometrial Cancers
This study is currently enrolling.Associated Conditions: Endometrial CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to find out if the combination of the drugs alpelisib and fulvestrant is better or worse than the usual approach for your type of cancer. The usual approach is defined as...